Gregory K Behbehani, MD, PHD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI’m a hematologist-oncologist and provide clinical, inpatient care of patients with acute myeloid leukemia and acute lymphocytic leukemia. I also serve as an assistant professor of internal medicine at The Ohio State University. I received my medical training at the University of Cincinnati, where I also earned a PhD in molecular genetics. I completed a fellowship in hematology and oncology at Stanford University, where I later completed a postdoctoral fellowship in the laboratory of Garry Nolan focusing on applying mass cytometry (CyTOF) to the characterization of clinical samples from patients with hematologic malignancies. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, my research laboratory is focused on using the single-cell deep functional phenotyping enabled by mass cytometry. That helps predict how novel therapeutic approaches might be optimally combined with current therapies to prevent treatment failures. The collegial, caring atmosphere at The James makes this not only a wonderful place to work but a great place to receive treatment too. Our multidisciplinary approach, combined with state-of-the-art science, helps patients have more efficient, targeted treatment and better outcomes.
Clinical Expertise
More info for- Myelodysplastic Syndromes
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Acute Myeloid Leukemias
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA
Internship - Internal Medicine
- University of Chicago School of Medicine
5841 S Maryland Ave, Chicago, IL
Residency - Internal Medicine
- University of Chicago School of Medicine
5841 S Maryland Ave, Chicago, IL
Medical School
- University of Cincinnati College of Medicine
231 Albert Sabin Way, Cincinnati, OH
- Stanford Hospital and Clinics
Academic Office & Contact Information
More info forAcademic Office:
Biomedical Research Tower 0416
460 W 12th Ave
Columbus, Ohio 43210-2210Email:
behbehani.1@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forJune 20, 2024BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics in vivo.
Canella A, Nazzaro M, Artomov M, Rao Venkata LP, Thomas D, Lyberger J, Ukhatov A, Xing YL, Miller K, Behbehani G, Amankulor NM, Petritsch CK, Rajappa P
Mol Ther Oncol
June 20, 2024Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.
Chu Y, Nayyar G, Tian M, Lee DA, Ozkaynak MF, Ayala-Cuesta J, Klose K, Foley K, Mendelowitz AS, Luo W, Liao Y, Ayello J, Behbehani GK, Riddell S, Cripe T, Cairo MS
Mol Ther Oncol
March 5, 2024Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, Cash AA, Behbehani G, Cao K, Schafer J, Champlin RE, Lee DA
Am J Hematol
September 4, 2023Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R
Leuk Lymphoma
July 28, 2023Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment.
Canella A, Nazzaro M, Rajendran S, Schmitt C, Haffey A, Nigita G, Thomas D, Lyberger JM, Behbehani GK, Amankulor NM, Mardis ER, Cripe TP, Rajappa P
Cell Rep
February 24, 2023A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L
Cancers (Basel)
December 30, 2022Manufacture and Characterization of GMP-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.
Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Venkata LPR, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, Johnson B, Wang Y, Cairo MS
J Infect Dis
June 25, 2022The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, Coss CC, Mace TA
Int J Mol Sci
June 20, 2022Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.
Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA
Cell Rep Methods
November 17, 2021PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, Xie Z, Chen M, Lapalombella R, Walker AR, Mims AS, Larkin K, Grieselhuber NR, Bennett C, Phelps MA, Hertlein E, Behbehani GK, Vasu S, Byrd JC, Muthusamy N
Blood
October 28, 2021Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients.
Koenig KL, Curley TP, Mani S, Keiter A, Zhao Q, Behbehani GK, Bhatnagar B, Blachly JS, Haque TZ, Larkin KTM, Long M, Mims AS, Vasu S, Wall SA, Byrd JC, Lustberg M, Walker AR, Grieselhuber NR
Hematol Oncol
October 22, 2021Use of the Pyrimidine Analog, 5-Iodo-2'-Deoxyuridine (IdU) with Cell Cycle Markers to establish Cell Cycle Phases in a Mass Cytometry Platform.
Devine RD, Behbehani GK
J Vis Exp
September 1, 2021Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C
Blood Cancer Discov
July 26, 2021Decrease post-transplant relapse using donor-derived expanded NK-cells.
Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE
Leukemia
June 14, 2021Pre-operative exercise therapy triggers anti-inflammatory trained immunity of Kupffer cells through metabolic reprogramming.
Zhang H, Chen T, Ren J, Xia Y, Onuma A, Wang Y, He J, Wu J, Wang H, Hamad A, Shen C, Zhang J, Asara JM, Behbehani GK, Wen H, Deng M, Tsung A, Huang H
Nat Metab
June 1, 2021Mass Cytometry, Imaging Mass Cytometry, and Multiplexed Ion Beam Imaging Use in a Clinical Setting.
Devine RD, Behbehani GK
Clin Lab Med
May 21, 2021Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS
Leukemia
March 24, 2021Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
Ozga M, Blachly J, Eisfeld AK, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims AS, Saygin C
Am J Hematol
November 2, 2020Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, Wesolowski R, Behbehani GK, Carson WE, Otterson GA
Clin Lung Cancer
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Behbehani has reported no relationships with companies or entities.
Patient Comments
Provider always answers all questions
Very pleased and satisfied with the experience.
He is always patient and answers all my questions.
Dr Behbehani never rushes you, takes time to explain options and involves the patient in their care. Very blessed to have him as my hematologist, I trust him fully.
Very pleased
Dr. Behbehani is very helpful and caring. He listens to my concerns.
I keep coming back due to the care, treatment, and kindness that the doctor provides. His knowledge and time are greatly appreciated by both me and my husband.
Dr. Behbehani has always treated me and my condition with the most up to date information and options available. He does not rush me through the appointment, and I feel he is the most knowledgeable about me and my condition as it relates to me